Carl Vance
Endocrinology, Diabetes & Metabolism · Idaho Falls, IDNPI 1437159423
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.6% of the total across 48 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Abbott at 41.2% of the total. Reporting peaked in 2022 at $214 and has fallen 72.7% since, to $58 in 2025.
Across 48 payments — averaging $15.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$300
- AbbVie$109
- Dexcom, Inc.$66
- Teva Pharmaceuticals USA, Inc.$41
- Bayer$39
- Inspire Medical Systems, Inc.$33
- plus $141 from 8 others
Across 979 payments — averaging $3789.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$3.2M
- Novo Nordisk AS$274K
- Ascensia Diabetes Care US Inc.$118K
- AbbVie$35K
- Astrazeneca UK Limited$19K
- Boehringer Ingelheim$10K
- plus $17K from 3 others
What the payments were for
- Food & beverage$69696%
- Education$324%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 26 | $300 |
| AbbVie(2 entities) | 5 | $109 |
| Dexcom, Inc. | 2 | $66 |
| Teva Pharmaceuticals USA, Inc. | 3 | $41 |
| Bayer | 3 | $39 |
| Inspire Medical Systems, Inc. | 1 | $33 |
| Novo Nordisk | 1 | $32 |
| Eton Pharmaceuticals, Inc. | 1 | $19 |
| Pfizer | 1 | $18 |
| Curonix LLC | 1 | $17 |
| Recordati_rare_diseases_inc. | 1 | $16 |
| Boston Scientific | 1 | $14 |
| Medtronic | 1 | $13 |
| Strongbridge US Inc. | 1 | $12 |
How this compares
Too few endocrinology, diabetes & metabolism providers in Idahoto place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 135 | $167,843 |
| TrulicityDulaglutide | 73 | $90,337 |
| Tresiba Flextouch U-200Insulin Degludec | 80 | $89,697 |
| JardianceEmpagliflozin | 95 | $83,728 |
| Tresiba Flextouch U-100Insulin Degludec | 106 | $61,795 |
| MounjaroTirzepatide | 56 | $59,625 |
| EliquisApixaban | 45 | $52,368 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $31,523 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 34 | $29,650 |
| Novolog FlexpenInsulin Aspart | 81 | $25,491 |
| Bydureon BciseExenatide Microspheres | 16 | $23,073 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 132 | $19,416 |
| FarxigaDapagliflozin Propanediol | 19 | $18,341 |
| Humalog Kwikpen U-100Insulin Lispro | 53 | $16,826 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 26 | $14,260 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog, Levemir | $32 | $176,394186 claims |
| PfizerEliquis | $18 | $52,36845 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few endocrinology, diabetes & metabolism providers in Idahoon file to place this against a meaningful peer group, so we don't.
Other endocrinology, diabetes & metabolism in Idaho Falls
- David LiljenquistIdaho Falls$9K
- John LiljenquistIdaho Falls$480
- Robert EnnisMeridian$69K
- Theodore RooseveltBoise$65K
- Julie FooteBoise$8K
- Katy ConnleyEagle$6K
- Adam LykoPost Falls$5K
- Shanaz SikderBoise$3K
- Angelo CapricchioneBlackfoot$2K
- Michael HolyoakMeridian$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.